Peptide Therapy for Weight Loss: How It Works
FAQs
Most patients notice reduced appetite and improved energy within 2–3 weeks of starting a GLP-1 or GH-stimulating peptide protocol. Measurable changes in body composition — reduced waist circumference and visible fat loss — typically appear between weeks 6 and 8. Full results are usually assessed at the 3-month mark, with optimal outcomes at 5–6 months.
When prescribed and monitored by a physician, peptide therapy has a favorable safety profile. The most common side effects with GLP-1 peptides (semaglutide, tirzepatide) are mild nausea, reduced appetite, and occasional injection site reactions — particularly in the first few weeks. GH-stimulating peptides (CJC-1295/Ipamorelin) may cause temporary water retention or tingling sensations. Serious adverse events are rare when protocols are dosed correctly and monitored with regular labs.
Most therapeutic peptides are administered via subcutaneous injection (under the skin, similar to insulin). The injections are very small gauge and most patients describe them as nearly painless. Some peptides — including certain GLP-1 analogs — are now available in oral tablet or nasal spray form, though injectable protocols typically offer higher bioavailability and more predictable dosing.
Weight regain is possible after stopping GLP-1 peptides if lifestyle habits haven’t changed — clinical trials show partial regain in the year following discontinuation. GH-stimulating peptide protocols tend to produce more durable results because they drive body recomposition (increased lean mass, reduced fat mass) rather than purely appetite suppression. The most sustainable outcomes combine peptide therapy with dietary and metabolic coaching, followed by a maintenance protocol designed by your physician.
Ozempic and Wegovy are brand-name pharmaceutical versions of semaglutide — a GLP-1 receptor agonist, which is itself a peptide. Peptide therapy as practiced in integrative and functional medicine clinics often includes compounded semaglutide alongside other peptides (such as CJC-1295, Ipamorelin, or AOD-9604) to create individualized multi-pathway protocols. This stacked approach targets fat loss, body recomposition, and metabolic health simultaneously, rather than appetite suppression alone.
Ideal candidates include adults with a BMI ≥ 27 with metabolic risk factors (insulin resistance, elevated triglycerides, pre-diabetes, hypertension), or a BMI ≥ 30 who have not achieved lasting results through diet and exercise. Peptide therapy is also commonly used by individuals with age-related metabolic decline, hormonal imbalances, or those seeking to preserve lean muscle during significant fat loss. A physician consultation with lab work is required to determine which peptides — and at what doses — are appropriate for your profile.
Costs vary by protocol and clinic. GLP-1-based protocols (compounded semaglutide) typically range from $200–$500/month, significantly less than brand-name Ozempic without insurance. GH-stimulating peptide stacks (CJC-1295 + Ipamorelin) generally run $150–$350/month. Most peptide therapy is not covered by insurance as it is prescribed outside of standard pharmaceutical channels. Many clinics offer bundled pricing that includes labs, physician oversight, and protocol adjustments.
References
- Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989–1002. → Read on NEJM
- Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205–216. → Read on NEJM
- Teichman SL, et al. (2006). Prolonged stimulation of growth hormone secretion by CJC-1295, a long-acting analog of GHRH. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. → Read on Oxford Academic
- Ng FM, et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278. → Read on PubMed
- Rubino DM, et al. (2022). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA, 327(14), 1368–1379. → Read on JAMA
- Freda PU. (2009). Current concepts in the biochemical assessment of the patient with acromegaly. Growth Hormone & IGF Research, 13(4), 171–184. → Read on P